Spots Global Cancer Trial Database for combination treatment
Every month we try and update this database with for combination treatment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses | NCT00774787 | Actinic Keratos... | imiquimod 5% cr... | 18 Years - | Rigel Dermatology | |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | NCT00498836 | Malignant Melan... | CP-4055 Sorafenib (Nexa... | 18 Years - | Clavis Pharma | |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | NCT01000896 | Cancer Non Small Cell ... Epithelial Ovar... | AZD0530 Carboplatin paclitaxel | 20 Years - | AstraZeneca | |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease | NCT01915303 | Cushings Diseas... | Pasireotide wit... | 18 Years - | Novartis | |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes | NCT03551626 | Malignant Melan... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | NCT03280030 | Acute Myeloid L... | Midostaurin Placebo | 18 Years - 70 Years | Novartis | |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | NCT02967692 | Melanoma | Spartalizumab Placebo Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer | NCT05288777 | Breast Cancer Breast Cancer S... Breast Cancer S... Breast Cancer S... | T-DM1 Capecitabine External Beam R... External Beam R... | 18 Years - | University of Virginia | |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | NCT01000896 | Cancer Non Small Cell ... Epithelial Ovar... | AZD0530 Carboplatin paclitaxel | 20 Years - | AstraZeneca | |
| A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | NCT03512197 | Acute Myeloid L... | Midostaurin Placebo Chemotherapy | 18 Years - | Novartis | |
| Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | NCT01322776 | Mantle Cell Lym... | Combination of ... | 18 Years - | Sun Yat-sen University | |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | NCT02967692 | Melanoma | Spartalizumab Placebo Dabrafenib Trametinib | 18 Years - | Novartis | |
| Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses | NCT00774787 | Actinic Keratos... | imiquimod 5% cr... | 18 Years - | Rigel Dermatology | |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | NCT00498836 | Malignant Melan... | CP-4055 Sorafenib (Nexa... | 18 Years - | Clavis Pharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
